The funds will be designated and used by Oramed Ltd to support further R&D and clinical study of its Oral Insulin capsule and Oral GLP1-Analog.
Oramed Pharmaceuticals CEO Nadav Kidron Esq said that they are pleased to have received the support of the Office of the Chief Scientist for the second year in a row.
"This grant will allow for further development of our product pipeline," Esq said.
Oramed Pharmaceuticals is a technology company deals with oral delivery solutions for drugs and vaccines presently delivered via injection.